Key result
Adding NT-proBNP to the TRS-HF DM score improves HF prediction in post-ACS T2D patients to C-index 0.82.
Why the study?
The TRS-HF DM prognosticates heart failure hospitalization in type 2 diabetes, but required external validation and extension for patients with recent acute coronary syndrome.
Does the addition of NT-ProBNP to the TRS-HF DM risk score improve risk stratification for heart failure hospitalization in patients with type 2 diabetes and recent acute coronary syndrome?
Observational (n=5,380)
Does the addition of NT-ProBNP to the TRS-HF DM risk score improve risk stratification for heart failure hospitalization in patients with type 2 diabetes and recent acute coronary syndrome?
Adding NT-ProBNP to the TRS-HF DM risk score significantly improves the prediction of heart failure hospitalization in patients with type 2 diabetes and recent acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
May refine HF risk stratification in T2D post-ACS; hypothesis-generating and requires prospective validation before practice change.
Aims The Thrombolysis in Myocardial Infarction Risk Score for Heart Failure (HF) in Diabetes (TRS‐HF DM ) prognosticates HF hospitalization in people with type 2 diabetes (T2D). This study aimed to externally validate and extend its use for those with recent acute coronary syndrome (ACS). Materials and Methods The TRS‐HF DM was externally validated in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial (n = 5380) and extended with natriuretic biomarkers. Missing data were multiply imputed. Initial TRS‐HF DM variables were previous HF (2 points), atrial fibrillation (1 point), coronary artery disease (1 point), estimated glomerular filtration rate <60 ml/min/1.73 m 2 (1 point), and urine albumin‐to‐creatinine ratio 30‐300 mg/g (1 point) and >300 mg/g (2 points). Results In total, HF hospitalization occurred in 193 (3.6%) patients. Based on the TRS‐HF DM , 25% of patients were classified as intermediate risk (1 point), 30% were classified as high risk (2 points), 19% were classified as very‐high risk (3 points) and 26% were classified as severe risk (≥4 points). Before model extension, discrimination (C‐index 0.76, 95%·CI 0.73‐0.80) and calibration (calibration slope 0.82, 95%·CI 0.65‐1.0; calibration‐in‐the‐large −0.15, 95%·CI −0.37‐0.64) were moderate‐to‐good in individuals with T2D and recent ACS. The extension of TRS‐HF DM with the addition of N‐terminal pro‐B‐type natriuretic peptide (NT‐ProBNP) improved discrimination (C‐index 0.82, 95%·CI 0.79‐0.85) and calibration (calibration slope 0.84, 95%·CI 0.66‐1.02; calibration‐in‐the‐large −0.12, 95%·CI −0.33‐0.081) for this higher‐risk population. Conclusion The TRS‐HF DM with the extension of NT‐ProBNP improves risk stratification and generalizes the use of the risk score for patients with T2D and ACS. Future validation studies in ACS populations may be warranted.
No takes yet. Share an insight, caveat, or question.
Razaghizad et al. (2022) conducted an observational in Type 2 diabetes with recent acute coronary syndrome (n=5,380). TRS-HF DM risk score extended with NT-ProBNP vs. Original TRS-HF DM risk score was evaluated on Heart failure hospitalization (C-index 0.82, 95% CI 0.79-0.85). Extending the TRS-HF DM risk score with NT-ProBNP improved discrimination for predicting heart failure hospitalization in patients with type 2 diabetes and recent ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: